NovoCure Limited vs Pfizer, Inc. — Stock Comparison
Q·Score Breakdown
5.4
Bearish
Overall
6.5
Neutral
Quality
Health
Growth
Valuation
Sentiment
NVCR
Healthy balance sheet and financial position.
⚠ currently unprofitable (-26% margin).
PFE
Strong profitability with 12% net profit margins.
⚠ analyst sentiment is cautious.
Analyst Consensus
BUY
Target $25.21 (+51.7%)
7 analysts
HOLD
Target $29.00 (+10.2%)
27 analysts
Fundamentals
NVCR
PFE
—
Trailing P/E
19.4×
-14.3×
Forward P/E
9.4×
-25.7%
Profit Margin
12.4%
75.4%
Gross Margin
75.8%
-50.0%
ROE
8.9%
12.3%
Revenue Growth
-1.2%
—
Earnings Growth
—
0.82
Beta
0.39
—
Price / Book
—
$1.9B
Market Cap
$149.8B
$10 – $20
52-Week Range
$22 – $29
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →